Ametantrone inhibits prostaglandin - mediated resorption in bone organ culture

Margaret R. Warner*, Mark S. Rappaport, Nancy S. Krieger, Raymond F. Novak, Paula H. Stern

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

5 Scopus citations


Prostaglandins (PG) have been postulated to be involved in both tumor metastases to bone and in tumor-induced bone resorption. The anthracenedione antineoplastic agents ametantrone (HAQ) and mitoxantrone are potent antioxidants and inhibit hydroperoxide-dependent initiation and propagation reactions. Therefore, these compounds may inhibit PG production and could also inhibit tumor metastases and tumor-induced resorption. The ability of HAQ, a prototypic anthracenedione, to inhibit PG synthesis and PG-mediated bone resorption was investigated using neonatal mouse calvaria in organ culture. Epidermal growth factor (EGF) stimulates bone resorption in this tissue by inducing PG synthesis. Consequently, if HAQ inhibits EGF-stimulated PG synthesis, it should also inhibit EGF-stimulated bone resorption. HAQ, at 10 μM, completely abolished EGF-stimulated PG synthesis and calcium release. Moreover, HAQ (1.0-30 μM) inhibition of EGF-stimulated PGE2 synthesis correlated with the inhibition of EGF-stimulated Ca release in a concentration-dependent manner. In contrast to EGF, parathyroid hormone stimulates resorption by a PG-independent pathway. HAQ at 10 μM had no effect on parathyroid hormone stimulated Ca release. These results suggest that HAQ inhibition of bone resorption appears to be primarily mediated by inhibition of PG biosynthesis.

Original languageEnglish (US)
Pages (from-to)469-476
Number of pages8
Issue number4
StatePublished - Oct 1984

ASJC Scopus subject areas

  • Biochemistry
  • Endocrinology


Dive into the research topics of 'Ametantrone inhibits prostaglandin - mediated resorption in bone organ culture'. Together they form a unique fingerprint.

Cite this